• Ernexa Therapeutics on May 6, 2026 reported new preclinical results for lead cell therapy candidate ERNA-101 used with PD-1 blockade in ovarian cancer models; results were presented with this announcement.
• Combination treatment produced complete tumor elimination in tested models, outperforming either approach alone.
• Studies showed durable long-term survival in treated animals, supporting a potential curative profile in these models.
• Data point to tumor microenvironment remodeling that could make checkpoint inhibitors more effective in immunologically “cold” tumors.
• Program positioned to support a first-in-human study in advanced ovarian cancer, with additional combination work underway to broaden potential solid-tumor use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060833PRIMZONEFULLFEED9714291) on May 06, 2026, and is solely responsible for the information contained therein.